Moderna Plunges 4% as $2.25B Patent Settlement and Earnings Downgrade Sour Sentiment
Moderna (MRNA) shares are tumbling Wednesday, significantly underperforming a flat S&P 500, as investors digest a massive $2.25 billion patent settlement with Roivant Sciences and a sharp downward revision to Q1 earnings estimates. The stock fell 4.41% to $45.06 in midday trading, while the broader market remained virtually unchanged.
Dual Blow: Legal Liabilities and Earnings Revisions
Moderna (MRNA) is facing a perfect storm of negative catalysts today, sending the stock down 4.41% to $45.06. This move represents a stark divergence from the broader market, with the S&P 500 (SPY) remaining nearly flat at -0.01%. The primary driver behind the sell-off is a dual blow of a multi-billion dollar legal settlement and a significant reduction in earnings expectations just ahead of the company's quarterly report.
The $2.25 Billion Roivant Settlement
A major weight on the stock today is the confirmation of a $2.25 billion global settlement with Roivant Sciences. The agreement resolves long-standing patent litigation regarding the lipid nanoparticle (LNP) technology used in Moderna's COVID-19 vaccines. Under the terms of the deal, Moderna is slated to make an initial payment of $950 million in July 2026, with an additional $1.3 billion potentially due depending on future court decisions. This substantial cash outflow comes at a critical time as the company navigates a transition away from its peak pandemic-era revenues and manages a high-cost clinical pipeline.
Analysts Slash Q1 Expectations
Compounding the legal news, analysts at Brookline Capital Markets have issued a drastic downward revision for Moderna’s Q1 2026 earnings. Analyst L. Cann more than doubled the projected loss for the quarter, moving the estimate from ($1.89) per share to ($4.31) per share. This revision reflects growing skepticism regarding the commercial trajectory of the company’s respiratory portfolio and the mounting expenses associated with its R&D efforts. The consensus estimate for the full year now sits at a loss of ($7.23) per share, highlighting the financial hurdles ahead.
Pipeline Costs and Market Context
The sell-off also follows Moderna's recent launch of a Phase 3 trial for its H5N1 bird flu vaccine (mRNA-1018). While the program has received support from global health groups, it has also highlighted the company's increasing reliance on self-funding after the U.S. government withdrew hundreds of millions of dollars in research support earlier this month.
With the stock now trading below its 20-day and 50-day moving averages, technical sentiment has soured alongside the fundamental news. Today's move suggests a "de-risking" by institutional investors ahead of the official Q1 earnings release, which is expected as early as tomorrow. Investors are clearly prioritizing the immediate cash impact of the Roivant settlement and the widening projected losses over the potential long-term value of the mRNA pipeline.
Key Takeaways
- Moderna agreed to a $2.25 billion settlement with Roivant Sciences over LNP technology, with a $950 million payment due in July 2026.
- Brookline Capital Markets more than doubled its projected Q1 loss for the company, slashing the EPS estimate to ($4.31) from ($1.89).
- The stock is sharply underperforming the S&P 500, which is flat on the day, reflecting a major divergence in sentiment.
- Investors are increasingly concerned about Moderna's cash burn as it funds late-stage trials for bird flu and combination vaccines without federal support.